key: cord-0888822-sgmw5sf8
authors: Liu, Qibin; Fang, Xuemin; Tian, Lu; Chen, Xianxiang; Chung, Ungil; Wang, Ke; Li, Dan; Dai, Xiyong; Zhu, Qi; Xu, Feng; Shen, Lei; Wang, Bing; Yao, Li; Peng, Peng
title: The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan
date: 2020-04-17
journal: nan
DOI: 10.1101/2020.04.11.20056523
sha: 8933d3de44a0b88fc3843c05a710e41e84b0b6a3
doc_id: 888822
cord_uid: sgmw5sf8

BACKGROUND The worldwide COVID-19 pandemic develops rapidly. There is a pressing need to find an effective therapy. METHODS We have assembled a cohort consisting 504 hospitalized COVID-19. Information of patients characteristics and antiviral medication use during hospital stay is collected. The study objective is to evaluate the treatment efficacy of selected antiviral medications on mortality and lesion absorption based on chest CT scan. RESULTS The overall mortality rate was 15.67% in the cohort. Older age, lower SpO2 level, bigger lesion, early admission data, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for sex, pre-existing condition, age, SpO2, lesion size, admission data, hospital, and anti-viral medications use, Arbidol and Oseltamivir use is associated with a reduction in mortality. The OR is 0.183 (95% CI, 0.075 to 0.446; p<0.001) for Arbidol and 0.220 (95% CI, 0.069 to 0.707; p=0.011) for Oseltamivir. Compared with patients taking neither Arbidol nor Oseltamivir, the OR is 0.253 (95% CI, 0.064 to 1.001; p=0.050) for patients taking Oseltamivir only; 0.190 (95% CI, 0.076 to 0.473; p<0.001) for patients taking Arbidol only; and 0.030 (95% CI, 0.003 to 0.310; p=0.003) for patients taking both, after adjusting for patients characteristics and Lopinavir/Ritonavir use. Similarly, Arbidol is also associated with faster lesion absorption after adjusting for patients characteristics as well as Oseltamivir and Lopinavir/Ritonavir use. CONCLUSIONS Arbidol is able to substantially associated with a reduction in mortality among hospitalized COVID-19 patients. The combination of Arbidol and Oselmativir may further associated with a reduction in mortality. There is no proven treatment benefit of Lopinavir/Ritonavir.

The worldwide COVID-19 pandemic develops rapidly. There is a pressing need to find an effective therapy.

We have assembled a cohort consisting 504 hospitalized COVID-19. Information of patients' characteristics and antiviral medication use during hospital stay is collected. The study objective is to evaluate the treatment efficacy of selected antiviral medications on mortality and lesion absorption based on chest CT scan.

The overall mortality rate was 15.67% in the cohort. Older age, lower SpO2 level, bigger lesion, early admission data, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for sex, pre-existing condition, age, SpO2, lesion size, admission data, hospital, and anti-viral medications use, Arbidol and Oseltamivir use is associated with a reduction in mortality. The OR is 0.183 (95% CI, 0.075 to 0.446; p<0.001) for Arbidol and 0.220 (95% CI, 0.069 to 0.707; p=0.011) for Oseltamivir. Compared with patients taking neither Arbidol nor Oseltamivir, the OR is 0.253 (95% CI, 0.064 to 1.001; p=0.050) for patients taking Oseltamivir only; 0.190 (95% CI, 0.076 to 0.473; p<0.001) for patients taking Arbidol only; and 0.030 (95% CI, 0.003 to 0.310; p=0.003) for patients taking both, after adjusting for patients' characteristics and Lopinavir/Ritonavir use. Similarly, Arbidol is also associated with faster lesion absorption after adjusting for patient's characteristics as well as Oseltamivir and Lopinavir/Ritonavir use.

Arbidol is able to substantially associated with a reduction in mortality among hospitalized COVID-19 patients. The combination of Arbidol and Oselmativir may further associated with a reduction in mortality. There is no proven treatment benefit of Lopinavir/Ritonavir.

Since December 2019, when first case of COVID-19 has been discovered in Wuhan, China 1 , more than 1,000,000 infections and over 50,000 deaths have been reported [2] [3] .

Since the outbreak, researchers around the world have been actively searching for effective therapies, which are urgently needed to control the pandemic and is associated with a reduction in the mortality among infected. There were several case reports about recovery of COVID-19 patients after receiving certain treatment 4-5 . However, the lack of data remained an obstacle for reliable evaluation of the treatment effect of therapies attempted. There are several on-going clinical trials, whose completion, however, requires more time and resources with uncertain result [6] [7] [8] [9] [10] [11] .

On March 4, 2020, the Chinese National Health Commission issued the "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Version 7)". The medications mentioned in the antiviral treatment program include Lopinavir/Ritonavir, Ribavirin, Chloroquine Phosphate, and Arbidol 12 . In addition, other antiviral drugs including Oseltamivir, Ganciclovir, Favipiravir and Remdesivir have also been used in clinical practice. Lopinavir/Ritonavir is commonly used in combination with other antiretroviral drugs to treat HIV infection [13] [14] . Ribavirin is an antiviral drug mainly used for viral pneumonia and bronchitis caused by respiratory syncytial virus 15 .

Chloroquine phosphate is originally used to treat chloroquine-sensitive falciparum, . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint vivax, and malaria 16 . Arbidol is mainly used to treat upper respiratory tract infections caused by influenza virus [17] [18] . Oseltamivir and Favipiravir are also primarily used to treat influenza 19, 20 . Ganciclovir is used for treating infections induced by cytomegalovirus, herpes simplex virus, and Epstein-Barr virus 21 . Remdesivir is a new drug, whose antiviral effect is unclear as relevant clinical trials are still ongoing 22 .

When COVID-19 pandemic started, Wuhan Pulmonary Hospital (WPH) became one of the first COVID-19 designated hospitals and had received more than 700 COVID-19 patients by March 29, 2020. Wuhan Tongji Hospital and Wuhan Union Hospital are also designated hospitals treating a large number of COVID-19 patients.

The clinical experience in battling COVID-19 in these three hospitals may guide the discovery of effective therapies of the disease. Our study objective is to evaluate the treatment effect of selected antiviral medications using real word data collected from these hospitals.

The study protocol was reviewed and approved by the Ethics committee of WPH (WPE 2020-12) . Patient records and information were de-identified prior to the analysis.

. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint Figure 1 demonstrates steps of constructing the cohort.

Treatment protocols in all three hospitals included Lopinavir/Ritonavir, and Arbidol. Some early protocols recommended Oseltamivir. With the development of the epidemic, Chloroquine Phosphate and Favipiravir had also been used for selected patients. The prescription of antiviral medications and their administration time for each patient were extracted from electronic medical records. In this study, we . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint specifically focus on the three most prescribed medications: Arbidol, Oselmativir, and Lopinavir/Ritonavir.

We collected data on patient characteristics having a known association with patients' outcome including age, sex, pre-existing conditions (eTable 1), SpO2 level at hospital admission, use of oxygen and ventilators during the hospital stay, and patient's first and the last available CT scan images.

The primary endpoint is in-hospital death, whose time is extracted from medical records. The secondary endpoint is the change in lesion size measured by CT scans.

We measured the lesion size based on the first CT image after the patient's admission but before the initiation of the regular full-course antiviral treatment. We also measured the lesion size based on the last CT scan taken before patient's death or discharge, which is normally after completing the antiviral therapy cycle. To ensure the comparability of the two CT images, we selected the plane with the largest lesion in the first CT scan, and took the same plane in the second. The lesion in the selected plane was circled and quantified (eFigure 1) by ImageJ by NIH 23 .

Patient characteristics at baseline were summarized according to treatment and . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint .

hospital. Continuous and dichotomous variables were summarized by their mean (standard deviation (SD)), and count (proportion), respectively. We compared the mortality rate between patients who received the selected medication, and those who did not using Fisher's exact test. We then employed the logistic regression to estimate the odds ratio (OR) associated with the medication after adjusting for sex, pre-existing condition, medication use, hospital, and log-transformed age, SpO2 level, admission data as well as the lesion size from the initial CT scan. Missing covariates were imputed by the medians of the observed values. We also performed sensitivity analysis to evaluate the causal effect of the treatment using doubly robust method 24 .

The analysis was restricted to patients whose estimated propensity scores were between 0.1 and 0.9 25 . We also repeated the logistic regression for patients in WPH only, where the potential sampling bias was the lowest. We checked the goodness of fit of the logistic regression with Hosmer-Lemeshow test 26 . In addition, we performed Cox regression analyses with time dependent covariates, setting value to 0 and 1 before and after the medication prescription, respectively, to account for the timing of medication use 27 . We also conducted linear regression analyses with the log-transformed ratio of lesion area at the second CT scan to that at the first as the outcome to study the effect of the antiviral medication on lesion absorption among surviving patients. A small value one was added to all lesions size to avoid log-transformation of zero. The two-sided statistical significance level was set at 0.05.

All statistical analyses were conducted using R 3.3.1 (The R foundation for Statistical Computing).

. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint

The cohort consists of 504 patients with confirmed COVID-19 infection from three hospitals: 373 patients from WPH, 100 patients from the Tongji Hospital, and 31 patients from the Union hospital. Table 1 females, and 262 (52.0%) had pre-existing conditions. The average age of the cohort was 59.5 (SD, 14.9) years old. The average SpO2 level at admission was 92.8% (9.3%). Patients admitted to the hospital early were more likely to receive Oseltamivir and Lopinavir/Ritonavir.

The overall mortality rate was 15.67%. The mortality was 9.39% among females, . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint Figure 3 summarized the analysis results for all three medications. eFigure 3 shows the distribution of the lesion absorption rates by medication.

. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint

Of the 373 patients from WPH, 200 patients took neither Arbidol nor Oseltamivir, and 127 patients took only Arbidol. In order to study the causal effect of Arbidol, we compared the mortality between these two groups, after excluding 22 patients with an estimated propensity score (based on sex, pre-existing condition, log(age), log(SpO2), log(baseline lesion size), log(admission data) and Lopinavir/Ritonavir use) greater than 0.9 or less than 0.1. The doubly adjusted mortality estimate was 18.06% (95% CI, 12.88% to 23.44%) for patients taking neither, and 7.03% (95% CI, 2.99% to 11.42%) for patients taking Arbidol only. Compared with patients taking neither, the OR was 0.343 (95% CI, 0.142 to 0.638; P<0.001) favoring Arbidol. eTable 2 summarized the patients' characteristics by treatment before and after propensity score reweighting.

Of the 373 patients in WPH, the mortality was 7.09% among patients taking Arbidol vs. 24 .57% among those not (OR=0.234, 95% CI, 0.103 to 0.481, P<0.001). After adjusting for sex, pre-existing condition, log(age), log(SpO2), log(lesion area), log(admission data), and antiviral medication use, Arbidol was significantly associated with a reduction in mortality (OR, 0.193; 95% CI, 0.071 to 0.520, P=0.001). 

In all analyses, the treatment effect of Arbidol on reducing mortality among hospitalized COVID-19 patients is strong and robust. The combined use of Arbidol and Oseltamivir appears to be able to further is associated with a reduction in the mortality. In . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 11.20056523 doi: medRxiv preprint addition, patients taking Arbidol shows faster lesion absorption, which is consistent with its effect on mortality. On the other hand, the benefit of Lopinavir/Ritonavir is inconclusive, which is in consistent with the finding of Cao et al. (2020) , where Lopinavir/Ritonavir has associated with a reduction in the 28-day mortality from 25.0% to 19.2% in a randomized clinical trial, but fails to reach the statistical significance threshold [4] . Recently, Xu et al, (2020) reported that the virologic conversion rate in 49 patients taking Arbidol was significantly higher than that in 62 patients only receiving standard care (59.2% vs 40.3%, P=0.048). In the same study, the patients taking Arbidol also had a higher chance of achieving lesion area absorption on CT images (55.1% vs 32.2%) 27 . Despite limited sample sizes, their results further corroborate our findings. Arbidol's duo role in inhibiting the fusion between the viral envelope and target host cell membrane and in anti-inflammation may be responsible for its efficacy 28, 29 .

Oseltamivir is normally prescribed for treating influenza and has no known effect on COVID-19 patients. However, influenza is clinically similar to COVID-19 and some patients have been infected by both COVID-19 and common Influenza 30 , which may exacerbate their clinical conditions. It is possible that a combo therapy including Oseltamivir can help this subgroup of patients due to the effectiveness of Oseltamivir in treating severe illness caused by Influenza.

There are several important limitations in the current study. The study is not a . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint .

randomized clinical trial, and therefore the estimated treatment benefit of Arbidol and Oseltamivir may be due to confounding effect. We have collected the information on known confounders including age, comorbidities, admission data, and disease severity measured through SpO2 and CT scan. However, there is always a risk of unmeasured confounders, which can explain the observed treatment effect. On the other hand, given the size of the observed benefit, the unmeasured confounding effect needs to be very strong to completely account for the estimated benefit. Secondly, we didn't account for the effect of important supporting treatment such as oxygen and ventilator use. Their availability and deployment may affect the estimated treatment effect. Thirdly, although the cohort size is not small, the patients from Tongji and Union hospitals are not necessarily the most representative samples of patients admitted into these hospitals.

For example, ICU patients in these two hospitals are not included. We have also excluded surviving patients not discharged from WPH, and consequently, the observed mortality rate among patients from WPH in this cohort is substantially higher than that among all patients admitted into WPH. These sampling biases may affect the generalizability of our findings. Furthermore, there are only 33 patients taking both Arbidol and Oseltamivir in the entire cohort, which limits the reliability of the estimated treatment benefit associated with the combination therapy. On the other hand, despite limited sample size and selective sampling, all identified risk factors in the current study are consistent with the literature 31 , which indirectly supports the validity of our findings on treatment efficacy. The association between admission data and mortality can also be explained by increasing medical resource. Lastly regarding the . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint adverse events, a few cases of nausea were observed in patients who have received Arbidol;

Loss of appetite were observed among patients who have received Oseltamivir; Diarrhea, nausea, vomiting, loss of appetite, and worsened sleep quality were observed in patients who have received Lopinavir/Ritonavir. However, since a large proportion of the patients have received multiple medications, due to the complexity of the nature of the adverse events, the study team did not summarize these data in this report. On the other hand, Arbidiol and Oseltamivir have been used to treat influenza patients for many years and the severe adverse event associated with the medicine has been rare 17,19 . Conclusion: in this cohort of 504 COVID-19 patients from three hospitals, Arbidol alone and in combination with Oseltamivir are associated with drastically associated with a reduction in mortality after accounting for all observed confounders.

. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . adjusting for sex, pre-existing condition, log(age), log(SpO2), hospital, log(lesion size) and log(admission data); Model 2: adjusting for confounders in Model 1 and medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir). . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint comparison of goodness of fit tests for the logistic regression model. Statistics in Medicine, 16(9) , 965-980. 27. Xu, R., Luo, Y. and Chambers, C., 2012. Assessing the effect of vaccine on spontaneous abortion using time dependent covariates Cox models. Pharmacoepidemiology and drug safety, 21 (8) . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20056523 doi: medRxiv preprint

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

WHO Coronavirus disease (COVID-2019) situation reports

Insight into 2019 novel coronavirus -an updated intrim review and lessons from SARS-CoV and MERS-CoV

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study

Clinical trials on drug repositioning for COVID-19 treatment

A prospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia

The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection (ELACOI) Available from

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

The clinical study of carrimycin on treatment patients with Covid-19

Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune activation in asymptomatic HIV-infected patients (HCQ01

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7), released by National Health Commission & National Administration of Traditional Chinese Medicine on

Pursuing use of optimal formulations for paediatric HIV epidemic control -a look at the use of LPV/r oral pellets and oral granules

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

Arbidol as a broad-spectrum antiviral: An update

The treatment of influenza and acute respiratory viral infections

Oseltamivir Treatment of Influenza in Children

Bethesda (MD): National Library of Medicine (US)

Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Image manipulation and analysis software

Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data

Dealing with limited overlap in estimation of average treatment effects